Interpace Diagnostics raises $13.7M in a common stock and warrant offering
Interpace Diagnostics announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock, and common warrants to purchase up to an aggregate of 12,500,000 shares of common stock. Each share of common stock and, as applicable, each pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $1.10. For each pre-funded warrant Interpace sells, the number of shares of common stock Interpace is offering will be decreased on a one-for-one basis. The common warrants will be immediately exercisable at a price of $1.25 per share of common stock and will expire five years from the date of issuance. Maxim Group LLC is acting as the sole book-running manager for the offering. WestPark Capital, Inc. is acting as co-manager.